ClinicalTrials.gg
RecruitingNCT07701694Updated Jul 31, 2026

Functional Evaluation in Patients With Urea Cycle Disorders (UCD) During a Driving Task

An observational study in Urea Cycle Disorder, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged 16 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by St. Jude Children's Research Hospital · Observational

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
60
Ages
16 Years to 40 Years
Sex
All
01

Study summary

This study is being done to understand how the brain works while people with urea cycle disorder (UCD) perform driving tasks that range from easy to difficult and to look at how that compares to traditional tests of thinking and attention.

Read the detailed description

Primary Objective

  • To use fNIRS to study brain functional behavior in subjects with UCD by measuring the changes in HbO, HbR and HbT concentrations versus healthy control volunteers during the baseline driving task on the left and right prefrontal cortex (LPFC, RPFC).

Secondary Objective

  • To include other cortical regions such as temporal and occipital regions, to investigate the neurocognitive changes in these regions which may or may not change with driving. Thus, we will measure changes in HbO, HbR and HbT concentrations during the baseline driving task in four more brain regions (left and right parietal and occipital regions, LPA, RPA, LOL, ROL).

This is a non-therapeutic, non-interventional study in which brain fNIRS (functional near-infrared spectroscopy) measures will be compared under simulated driving conditions between patients with UCD vs. age and sex-matched control participants.

Participants who agree to participate will have Information about their medical history collected, have a basic neurological exam and answer questions about their health, diet, and driving habits. They will complete some simple thinking and memory tests. These tests will help investigators understand skills like memory, attention, and problem-solving. Participants will also wear a soft cap with small sensors called an fNIRS (functional near-infrared spectroscopy) device while they complete a driving simulator activity. This cap is noninvasive and measures how the brain uses oxygen while they drive in the simulator.

All study activities will be completed on the day of enrollment.

02

Conditions studied

  • Urea Cycle Disorder

Keywords

  • Participants with Urea Cycle Disorder
  • Healthy Volunteers
  • Cognitive function examination
  • Motor function examination
  • Simulated driving task with functional near-infrared spectroscopy monitoring
03

In context

Urea Cycle Disorders, Inborn

66 studies on the registry are indexed under Urea Cycle Disorders, Inborn; 14 are open to participants now.

This study's planned enrollment of 60 is above the median of 46 across 23 observational studies indexed under Urea Cycle Disorders, Inborn.

Browse Urea Cycle Disorders, Inborn studies →

Lead sponsor

St. Jude Children's Research Hospital is the lead sponsor of 440 studies on the registry; 102 are open to participants now.

Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Individuals who meet the Eligibility Criteria and agree to participate.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals 16 to 40 years with molecular or biochemical confirmation of a urea cycle disorder.
  • Healthy individuals will serve as an age and sex matched comparison group. Active driver's license for at least 6 months
  • Read and understand English. as the tasks have not been validated in other languages
  • IQ >=70.

Exclusion criteria

Exclusion Criteria:

  • Skin disease that affects the scalp
  • Past or present vascular disease
  • Head trauma with loss of consciousness in the last year or evidence of cognitive impairment due to and persisting after head trauma
  • Motor movement disorder which may cause excessive movement or impede use of the steering wheel and/or pedal
  • Premature birth or birth before 32 weeks of gestation
  • The participant is taking a stimulant or antidepressant
  • Allergy to any component of the device, although expected to be rare
  • History of psychosis
  • Self-reported motion or cyber sickness
  • Self-reported illicit substance use
  • Vision disorder
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • UCD group

    Participants with urea cycle disorders (UCD) who meet the Eligibility Criteria and consent to participate

  • Control group

    Healthy controls who meet the Eligibility Criteria and consent to participate

06

What researchers measure

Primary outcomes

  1. Changes in Oxyhemoglobin (HbO), Deoxyhemoglobin (HbR) and Total Hemoglobin (HbT) concentrations in the right and left prefrontal cortex in participants with urea cycle disorders (UCD) compared to healthy control volunteers

    Investigators will compare prefrontal cortex hemoglobin concentrations during low cognitive load between patients with UCD and healthy age and sex matched control participants using functional near-infrared spectroscopy (fNIRS). Mean values of hemoglobin concentration differences on the right and left prefrontal cortex between individuals, with and without UCD, during the low cognitive load task will be calculated and compared using two sample t-tests (for normally distributed data) or Wilcoxon rank sum tests (for nonnormally distributed data). P values will be adjusted for multiple comparisons using the Bonferroni method.

    Time frame: Day 1, during driving simulator task

Secondary outcomes

  1. Changes in HbO, HbR and HbT concentrations in the left and right parietal and occipital brain regions in participants with urea cycle disorders (UCD) compared to healthy control volunteers

    Investigators will compare left and right parietal and occipital regions hemoglobin concentrations during low cognitive load between patients with UCD and healthy age and sex matched control participants using functional near-infrared spectroscopy (fNIRS). Mean values of hemoglobin concentration differences on the left and right parietal and occipital regions between individuals, with and without UCD, during the low cognitive load task will be calculated and compared using two sample t-tests (for normally distributed data) or Wilcoxon rank sum tests (for nonnormally distributed data). P values will be adjusted for multiple comparisons using the Bonferroni method.

    Time frame: Day 1, during driving simulator task

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Aug 2031, 61 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 14, 2026
StartActual
Jul 20, 2026
Primary completionEst.
Aug 2031
CompletionEst.
Aug 2032
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07701694
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Jul 20, 2026
Primary completion
Aug 2031 (estimated)
Completion
Aug 2032 (estimated)
Last update
Jul 31, 2026

Study contacts

Jean Laboe, RN
Contact
jean.laboe@stjude.org
901-595-1693
Andrea Gropman, M.D.
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion